drugset / Trial / NCT04945421
IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b/II, open label, multicenter study of IBI310 (Anti-CTLA4 mAb) in combination with Sintilimab in patients with recurrent/metastatic Nasopharyngeal Carcinoma that failed prior Anti-PD-1/PD-L1 therapy
Timeline
- Start
- 2021-07-23
- Primary completion
- 2022-04-25
- Completion
- 2023-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI310 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | IBI310 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.